ARS PHARMACEUTICALS INC (SPRY:NASDAQ)
$8.5 0.33 (4.0392%)
Analysed ARS PHARMACEUTICALS INC (SPRY:NASDAQ) News Sources
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
07-05-2026
yahoo.com
Cronos Group (CRON) Q1 Earnings Meet Estimates
11-05-2026
yahoo.com
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
13-05-2026
yahoo.com
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
14-05-2026
yahoo.com
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
15-05-2026
yahoo.com
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates
15-05-2026
yahoo.com
ARS Pharmaceuticals Q1 Earnings Call Highlights
15-05-2026
marketbeat.com
Sector Update: Healthcare Stocks Decline Late Afternoon
15-05-2026
yahoo.com
ARS Pharmaceuticals Inc (SPRY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
15-05-2026
yahoo.com
ARS Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
16-05-2026
moby.co
What is the current price of ARS PHARMACEUTICALS INC (SPRY:NASDAQ)?
The current price of ARS PHARMACEUTICALS INC (SPRY:NASDAQ) is $8.5.
ARS PHARMACEUTICALS INC (SPRY:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARS PHARMACEUTICALS INC (SPRY:NASDAQ) since the previous trading day is $0.33.
ARS PHARMACEUTICALS INC (SPRY:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARS PHARMACEUTICALS INC (SPRY:NASDAQ) since the previous trading day is 4.0392%.
What is the most recent average sentiment score for ARS PHARMACEUTICALS INC (SPRY:NASDAQ)?
The most recent average sentiment score for ARS PHARMACEUTICALS INC (SPRY:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for ARS PHARMACEUTICALS INC (SPRY:NASDAQ)?
The most recent sentiment for ARS PHARMACEUTICALS INC (SPRY:NASDAQ) is .
SEC-8K** Filing Available For ARS PHARMACEUTICALS INC (SPRY:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.